Where we are: The Footsie is grinding out a modest 0.3% gain to trade around 8,215, staging a partial recovery from yesterday’s post-BoE slide but remaining on track for a 0.5% weekly loss. Intraday price action has established a firm base above the 8,180 support level, though the upside is capped by strong resistance at 8,250. Sector performance is highly bifurcated today, as strong gains across defensive pharma and heavyweight energy majors are fighting a rear-guard action against heavy selling in domestic lenders and diversified miners.
What’s driving it: UK retail sales rebounded sharply by 1.2% m/m in May, easily beating the 0.5% forecast and signaling resilient consumer demand that complicates the Bank of England’s path after keeping the Bank Rate at 3.75% yesterday. Adding to the domestic cross-currents, the PRA’s 06:00 BST release of Basel 3.1 internal model approach adjustments has triggered a sell-off in domestic banks, with Lloyds sliding 1.8% and Barclays down 0.9% on regulatory compliance jitters. This financial drag is being offset by defensive pharmaceutical strength—led by AstraZeneca’s 1.6% advance—and a recovery in oil majors BP and Shell as WTI crude stabilizes at $84.65 per barrel.
- UK Core CPI ticking up to 2.6% in May alongside a tight 4.9% unemployment rate validates the BoE’s hawkish hold at 3.75% and limits the scope for near-term monetary easing.
- Retail sales outperformance (+1.2% vs. 0.5% expected) underscores robust household balance sheets but keeps upward pressure on short-end gilt yields, flattening the UK curve.
- The PRA’s Basel 3.1 internal model approach consultation at 06:00 BST has injected fresh regulatory uncertainty into the banking sector, directly penalizing domestic lenders like Lloyds and NatWest.
NY session focus: As we transition to the New York open, the focus turns to the US 08:30 ET macro data, where any signs of US growth resilience will bolster global risk assets but could push US 10-year real yields above their current 2.23% level, creating a headwind for the index’s mining sector. The tactical trade is to buy defensive UK large-caps like AstraZeneca above 12,000p, while the long-financials trade looks highly vulnerable to a deeper correction below the FTSE 8,180 support. Watch the 8,250 level closely; a clean break above this opens the door to 8,310, whereas a breakdown below 8,150 invalidates the daily recovery thesis. The pain trade is a sharper-than-expected squeeze higher in global yields that forces a rapid unwind of rate-sensitive growth proxies, driving the FTSE 100 back down toward its weekly lows of 8,120.